Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

Next Previous
X
Search
Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease; Rectal fistula
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Divergence2
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 11 Oct 2022 Results of radiologic evaluation of Filgotinib treatment in perianal fistulizing Crohns Disease using a The Perianal Fistula Activity Index (PFAI), presented at the 30th United European Gastroenterology Week
    • 17 Mar 2021 Status changed from active, no longer recruiting to completed.
    • 17 Mar 2021 This trial has been completed in Czech Republic (Global End Date: 17 Feb 2021).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top